Ask AI
FIGHT-302
FIGHT-302: Phase III Trial of Pemigatinib as First-line Treatment for Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

Released: June 11, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: June 11, 2026